Search Results
You are looking at 1 - 3 of 3 items for
- Author or Editor: Bradford G. Bentz x
- Refine by Access: Content accessible to me x
Objective
To determine seroprevalence of Sarcocystis neurona-specific antibodies in a population of horses residing in Chester County, Pa.
Design
Prevalence survey.
Sample Population
117 serum samples from selected members of a population of 580 Thoroughbred horses.
Procedure
Serum was analyzed for antibodies to Sarcocystic neurona, using a western blot. Information regarding age, sex, and housing of horse was obtained by questionnaire. Data were analyzed, using multivariable logistic regression.
Results
Seroprevalence was 45.3% (95% CI, 36.3 to 54.3%). A relationship was not found between seroprevalence and sex of horse. Seroprevalence was greater in older horses (logistic regression; P = 0.16).
Clinical Implications
High seroprevalence of antibodies to S neurona and the lack of neurologic deficits among horses sampled indicate that positive results of serologic examination alone are of limited value for diagnosis of equine protozoal myeloencephalitis. Clinical signs consistent with the disease are the most important consideration in accurate diagnosis. (J Am Vet Med Assoc 1997;210:517–518)
Abstract
OBJECTIVE To determine whether prophylactic administration of valacyclovir hydrochloride versus initiation of treatment at the onset of fever would differentially protect horses from viral replication and clinical disease attributable to equine herpesvirus type-1 (EHV-1) infection.
ANIMALS 18 aged mares.
PROCEDURES Horses were randomly assigned to receive an oral placebo (control), treatment at detection of fever, or prophylactic treatment (initiated 1 day prior to viral challenge) and then inoculated intranasally with a neuropathogenic strain of EHV-1. Placebo or valacyclovir was administered orally for 7 or 14 days after EHV-1 inoculation or detection of fever (3 horses/group). Effects of treatment on viral replication and clinical disease were evaluated. Plasma acyclovir concentrations and viremia were assessed to determine inhibitory concentrations of valacyclovir.
RESULTS Valacyclovir administration decreased shedding of virus and viremia, compared with findings for control horses. Rectal temperatures and clinical disease scores in horses that received valacyclovir prophylactically for 2 weeks were lower than those in control horses. The severity of but not the risk for ataxia was decreased by valacyclovir administration. Viremia was decreased when steady-state trough plasma acyclovir concentrations were > 0.8 μg/mL, supporting the time-dependent activity of acyclovir.
CONCLUSIONS AND CLINICAL RELEVANCE Valacyclovir treatment significantly decreased viral replication and signs of disease in EHV-1–infected horses; effects were greatest when treatment was initiated before viral inoculation, but treatment was also effective when initiated as late as 2 days after inoculation. During an outbreak of equine herpesvirus myeloencephalopathy, antiviral treatment may be initiated in horses at various stages of infection, including horses that have not yet developed signs of viral disease.
